Brief: Atea Pharmaceuticals Will Review, Evaluate Proposal From Concentra Biosciences
23/05/2023 22:36
May 23 (Reuters) - Atea Pharmaceuticals Inc AVIR.O :
* ATEA PHARMACEUTICALS INC: WILL CAREFULLY REVIEW AND
EVALUATE
PROPOSAL FROM TANG CAPITAL PARTNERS' AFFILIATE, CONCENTRA
BIOSCIENCES
Source text for Eikon: ID:nGNXbYyyL7
Further company coverage: AVIR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM